In terms of per capita GDP, citizens of Bangladesh are likely to be richer than Indians in 2020, as well as five years later as per IMF projections. The report is  worrisome as it projects India slipping behind Bangladesh in per capita GDP due to a double-digit contraction in economy - IMF predicted 10.3 per cent de-growth in Indian GDP as against 3.8 per cent GDP growth for Bangladesh. But is really fair to compare the two economies? There are some challenges Bangladesh is bound to face in the future as it becomes a developing economy. Rajeev Dubey, Editor, Business Today, explains more. Read: Infographic: The Rise of Bangladesh

Just as equity investors gravitate towards the best stocks in crises, MBA aspirants too rush to the best B-Schools in times of uncertainty

The government has announced two schemes to boost the spending power of working Indians ahead of the festive season. These are the LTC cash voucher scheme and the Special Festive Advance scheme. The festive bonanza aims to revive demand but experts feel these will have a limited impact. Rajeev Dubey, Editor, Business Today explains the possible impact of these steps on demand. Watch the video for more.Also Read: 20 states allowed to raise Rs 68,825 crore to meet revenue shortfall

Despite the gloom and doom surrounding us, if there's anything that brings a ray of hope to the Indian economy right now, it's rural India

With GDP contracting 24 per cent in first quarter, economic recovery will be a long and painful process. Business Today's Rajeev Dubey, Dipak Mondal and Joe C. Mathew caught up with Chief Economic Advisor Krishnamurthy Subramanian on the state of the economy and plans to put it back on track. Edited excerpts:

This special issue is packed with an outstanding selection of those who represent half of humanity. Who stand out in the world of business and economy and wield power as responsibly as they lead-India's Most Powerful Women in Business & Economy

Phase 2/3 COVID-19 vaccine trials being conducted across 17 sites in India paused till further instructions from regulator; could delay vaccine development process as Serum Institute is front-runner when it comes to companies producing COVID-19 vaccines in India

Serum Institute CEO, Adar Poonawalla, told BusinessToday that the Indian trials, which were being conducted on the Oxford vaccine, had not been stopped yet. AstraZeneca PLC, which is working with a team of the University of Oxford, on Wednesday decided to temporarily pause the clinical trial of its coronavirus vaccine after one of the volunteers in the UK developed an 'unexplained' illness. Watch the video for more.Also Read: India coronavirus vaccine trials 'not stopped yet': Serum's Adar Poonawalla after AstraZeneca halts global trials

Serum Institute of India CEO, Adar Poonawalla, has said that the trials in India have not stopped even after AstraZeneca halted global trials of the vaccine after trial volunteer fell ill in the UK. The Serum Institute will be manufacturing the potential vaccine developed by Oxford University in collaboration with AstraZeneca.

\"AstraZeneca has paused the trials due to some unrelated issue with a patient in the UK, and we'll have to wait for AstraZeneca to explain what happened but this is not vaccine-related,\" says Poonawalla

Measures may have a short push, but they will have a 'steroid effect', says Chief Economic Advisor K Subramanian

The Indian government on Wednesday issued a list of 118 Chinese apps that are now banned in the country over security, surveillance, and data concerns. These apps include PUBG Mobile Nordic Map: Livik, PUBG Mobile LITE, VPN for TikTok, WeChat Work, AppLock, and others. The ban is a blow for Tencent in India whose PUBG, a battle royale game, is a smash-hit in the country. But, what impact will the move have on China? Rajeev Dubey, Editor, Business Today explains.Also Read: PUBG ban: Tencent to engage with Indian govt to ensure app's availability

It's easier to generate wealth, but far more difficult to manage it. Managing it responsibly is the mantle increasingly being taken over by Family Offices - the newest concept in the progression from the age-old munim to HUFs to Trusts to holding companies

With one major economic engine practically flat since 2013, India was still chugging along. Then, with domestic economy beginning to slow down, the second engine - private investment - started sputtering

Prime Minister Narendra Modi on Thursday launched 'Transparent Taxation- Honoring the Honest' platform, which included Faceless assessment, faceless appeal and taxpayer charter systems. PM Modi said that the Charter system would add strength to the government's efforts of reforming and simplifying the tax system and benefit several honest taxpayers, whose hard work powers national progress. Rajeev Dubey, Editor, Business Today explains the new Taxpayers' Charter. Watch the video for more.Also Read: Taxpayers' Charter: What taxpayers can expect from Income Tax department

Eventually everything rests on the Future of the Economy. Former RBI Deputy Governor Viral Acharya reminds us that an inter-dependent, inter-connected world is vital to the growth of the global economy

Top Indian and global CEOs and experts on why the future is bright

Gold prices have been touching new highs in India and global markets as investors seek safer investment options in the times of economic uncertainty. Gold prices have topped the Rs 50,000 mark and they are likely to spike further in the next 12 months. Rajeev Dubey, Editor, Business Today, explains the reasons behind this sudden spike in prices.Also Read: Sensex far from lifetime high, but PE ratio is still zooming

When historians chronicle India's coronavirus-induced business collapses, Biyani's Future Group is unlikely to go unnoticed

Sharks in the pharma supply chains are stockpiling and black-marketing a key life-saving drug for Covid-19, an India Today investigation has found. Remdesivir, produced by America's Gilead Sciences, is touted as the best hope for critically-ill coronavirus patients for its ability to shorten recovery times in clinical trials. India Today's undercover investigation has found that those who need remdesivir to keep them alive may not be able to afford it because of its excessive pricing on the black market. But, who's at fault? Rajeev Dubey, Editor, Business Today explains.Also Read: Coronavirus vaccine update: COVAXIN human trials start at PGI Rohtak